[Information provided by:
ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]
|NCT01088035 : Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma|
|Ages||Min: 12 Months Max: 21 Years|
- Patients must be enrolled before treatment begins.
- Patients must be ? 12 months and < 22 years of age at the time of diagnosis.
- The target tumors are primary brain non-metastatic (M0) ependymomas tumors.
Patients must have histologic verification of an ependymoma at diagnosis. Patients
with the following world health organization (WHO) diagnoses will be eligible for
this study:Ependymoma (Subtypes: cellular, papillary, clear cell and tanycytic)
and Anaplastic Ependymoma
- Life expectancy of ? 8 weeks.
- Newly diagnosed ependymoma and must not have had any prior chemotherapy or
- All patients must have:
- A pre-operative MRI scan of the brain with and without contrast. NOTE: CT scans
are NOT sufficient for study eligibility since radiation therapy planning and
responses will be based on MRI scans only.
- Post-operative head MRI scan with and without contrast (preferably within 72
- Spinal MRI (T-1 weighted imaging with and without gadolinium) is required within
28 days of surgery if done post-operatively and within 14 days of surgery if
done pre-operatively. For posterior fossa tumors, pre-operative MRI scans are
preferred because surgically induced inflammation/blood can be difficult to
distinguish from tumor.
- Lumbar CSF cytology examination obtained between 7 and 31 days following
- Adequate bone marrow function, defined as:
- Peripheral absolute neutrophil count (ANC) >1500/?L
- Platelet count ? 100,000/?L (transfusion independent)
- Hemoglobin ? 10.0 gm/dl (may receive RBC transfusions)
- Adequate renal function defined as:
- Serum creatinine < 1.5 times the upper limit of normal based on the patient's
age, or creatinine clearance greater than 60 ml/min/1.73 m² corrected for age
and body surface area.
- Adequate liver function defined as:
- Total bilirubin <1.5 x the institutional normal
- SGOT (AST) or SGPT (ALT) <2.5 x institutional normals.
- Patients must begin chemoradiotherapy within 56 days of definitive surgery.
- All patients and/or their parents or legal guardians must sign a written informed
- Patients must provide assent as per local IRB guidelines (if applicable).
- Patients and/or their families must consent to the mandatory biology studies,
including serum Survivin levels, CSF Survivin levels, paraffin-embedded tissue and
fresh-frozen tissue when available.
- Karnofsky/Lansky scoring greater than 50.
- Corticosteroid supportive care is permissible at the clinician's discretion prior to
and during chemo-radiotherapy.
- Anti-seizure medication support is permitted as necessary and at the treating
- Prior chemotherapy or prior radiotherapy
- Patients who are pregnant or breast feeding, or patients (male or female) not
employing adequate contraception. Acceptable means of birth control include IUD,
oral contraceptive, subdermal implant, a condom with a contraceptive sponge or
suppository or abstinence.
- Patients who are unable to undergo MR imaging
- Patients with evidence of metastatic disease on spine MRI or CSF sampling
- Patients with post-operative residual tumor > 0.5 cm, unless a repeat surgery is
performed making the residual tumor less than 1.5 cm². Note: Timing for enrollment
and initiation of therapy will begin after second surgery if a repeat surgery is
|Links||Permanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01088035
| Link to official Clinicaltrials.gov listing